Marty Makary resigned as Commissioner of the U.S. Food and Drug Administration on Tuesday, May 12, 2026 [1].
The departure of the agency's top official marks a significant shift in the administration's approach to public health regulation. The vacancy comes amid escalating tensions between the FDA's scientific leadership and the White House regarding the approval process for consumer products.
Makary's exit followed weeks of clashes with President Donald Trump and White House advisers [2]. The primary point of contention involved the FDA's handling of flavored e-cigarette approvals, and other controversial agency decisions [2]. Reports indicate that Makary had been slow-walking the approval of these products, which irked the president [3].
President Trump confirmed the departure as he left the White House on Tuesday while en route to China [2]. While some reports state Makary resigned due to policy disagreements, other accounts suggest he announced his resignation after reports surfaced that President Trump planned to fire him [3].
This transition represents the fourth high-profile departure from the Trump administration in 2026 [4]. The turnover at the FDA highlights a broader pattern of friction within the executive branch this year as the administration seeks to align agency operations with presidential priorities.
The FDA is responsible for protecting public health by ensuring the safety and efficacy of drugs, biological products, and medical devices. The current dispute over vaping regulations underscores the tension between clinical caution and the political desire for faster market approvals.
“Marty Makary resigned as Commissioner of the U.S. Food and Drug Administration on Tuesday, May 12, 2026.”
The resignation of Marty Makary suggests a pivot toward a more deregulatory approach at the FDA, particularly regarding the vaping industry. By removing a commissioner who resisted the rapid approval of flavored e-cigarettes, the administration is likely clearing the path for a successor more aligned with the president's preference for faster market access and reduced agency friction.
